When you buy through tie-in on our site , we may earn an affiliate commission . Here ’s how it works .
Men with advanced prostate genus Cancer may be longer after encounter a unexampled eccentric of targeted radiation sickness treatment , a new subject field suggests .
In the bailiwick , men given the discourse — a radioactive drug that specifically aim tumors in bone — live 14.9 calendar month on modal after their diagnosis , while those who received the placebo lived 11.3 calendar month , meaning the drug extended life by about 3.5 months .
All patient role in the study had castration - resistant prostate cancer , which is malignant neoplastic disease that come back despite operative or drug treatments to humble testosterone level .
About 30,000 U.S. men die from prostate cancer each year , often from Cancer the Crab that has spread to the bone . Many patients how have emasculation - tolerant prostate cancer and bone tumors can not encounter chemotherapy because they are too frail , the researchers read . [ See5 Things You Should Know About Prostate Cancer ] .
The new drug , called radium-223 bichloride ( marketed as Xofigo ) , mimicker calcium , and constipate to parts the bone that are rapidly divide — a machine characteristic of tumor site . Because the radiation syndrome is targeted to the bone tumors , damage to other tissue paper , including bone marrow , is minimized , the researchers said .
" You ’re using a content that naturally wants to go to where the cancer is , " said Dr. Neha Vapiwala , a radiation sickness oncologist and Associate Professor at the University of Pennsylvania , who was not involved in the study .
The treatment also had the additional benefit of improving caliber of life , such as relief from pain , for some affected role , Vapiwala said .
The Food and Drug Administration approved the drug , called Xofigo , in May , base on former results from the study . The bailiwick was funded by Bayer HealthCare , which makes Xofigo .
The drug has the potentiality to be used to treat other cancers that spread to osseous tissue , Vapiwala say .
Improved survival
The study include 921 men in 19 state with castration - repellent prostate cancer that had spread to their castanets , but not to other organs . All patients had symptoms such as bone pain or faulting . The average age was 71 .
affected role were willy-nilly assigned to receive either an shot of radium-223 every four week ( a total of six injection ) , or a placebo . All patients received the best tutelage for their disease , which often include other discourse , such asradiation treatmentand hormone to block the output of testosterone .
At the end of the field of study , 528 patients had died , including 54 percent of those in the radium-223 group , and 64 percent of those in the placebo mathematical group .
Radium-223 did not increase the endangerment of serious side result compare to the placebo . The most usual side gist were nausea , diarrhea , vomiting and swelling of the leg , articulatio talocruralis or fundament .
The report is print in the July 18 outlet of the New England Journal of Medicine .
Concerns about cost
Dr. David Samadi , chairperson of urology at Lenox Hill Hospital , said that drugs like Xofigo are last - resort handling for prostate Crab , used when other treatments such as surgery and radiation have fail to thwart cancer advancement . While other drugs be foradvanced prostate genus Cancer , so far , they are similar in effectiveness , adding about two to three months of biography , Samadi said .
One vexation about these new treatments is their high toll — Xofigo costs $ 69,000 for six injections , Bayer said .
" They ’re adding two to three month , for a immense cost . The dubiousness is , for someone who is dying , what do those three months think ? " Samadi say . Doctors and patients demand to weigh the risks and benefit of the drugs before deciding to use them , he added .
Another treatment , bid Sipuleucel - tetraiodothyronine ( Provenge ) , a prostate cancer vaccinum , costs nearly $ 100,000 and widen lifetime by about four calendar month .
Bayer and the society spouse Algeta " are committed to ensuring that patients who miss insurance policy or have other fiscal needs and who postulate Xofigo have approach to the treatment , " Rose Talarico , deputy director of communications at Bayer , said in an email to LiveScience . The companies have set up a program to assist in find reporting for patient who involve it , Talarico say .
It ’s not clear if the drug would help patient with expurgation - resistant prostate cancer that has spread to other organs in increase to bone . Up to 25 per centum of patient with expurgation - tolerant prostate cancer have tumors that diffuse to internal organs , the researchers read .
